An Open-Label Phase 1/2A Study of GV20-0251 in Participants With Advanced and/or Refractory Solid Tumor Malignancies
Latest Information Update: 29 Jul 2025
At a glance
- Drugs GV20-0251 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors GV20 Oncotherapy
Most Recent Events
- 29 Jul 2025 New trial record